Výsledky vyhledávání - "Olivier Le Brun"

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

Autor: Edward V Loftus, Séverine Vermeire, Brian G Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J Sandborn, Toshifumi Hibi

Background and Aims Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fac7c5a8300e32bb40854ac22960ca48
https://lirias.kuleuven.be/handle/20.500.12942/702613

Zobrazit plný text záznamu

Akademický článek

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Autor: Rogério Souza, Richard N Channick, Marion Delcroix, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Loïc Perchenet, Tomás Pulido, B K S Sastry, Olivier Sitbon, Adam Torbicki, Lewis J Rubin, Gérald Simonneau

Publikováno v: PLoS ONE, Vol 13, Iss 3, p e0193226 (2018)

Patients with pulmonary arterial hypertension who achieve a six-minute walk distance of 380-440 m may have improved prognosis. Using the randomized controlled trial of macitentan in pulmonary arterial hypertension (SERAPHIN), the association between

Externí odkaz: https://doaj.org/article/c3fc362044664c44b09c2c2b93bdaf8c

Zobrazit plný text záznamu

Plný text ve formátu HTML

D5.3 - PEI Definition and Algorithms v2

Autor: Carlos E. Palau, Ignacio Lacalle, Andreu Belsa, Charles Garnier, Erwan Simon, Olivier Le Brun, Deborah Mille, Luka Traven, Matija Siroka, Stjepan Pilicic, Teodora Milosevic

This deliverable describes the methodology for PEI computation including the eKPIs to be used, the statistical algorithms as well as a description of the data sources which will be used

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::970270e4671384613c911c4214ba3aa0

Zobrazit plný text záznamu

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension

Autor: Lewis J. Rubin, Marion Delcroix, Nazzareno Galiè, Tomás Pulido, Richard N. Channick, B.K.S. Sastry, Adam Torbicki, Olivier Sitbon, Pavel Jansa, Rogério Souza, Loïc Perchenet, Gérald Simonneau, Hossein Ardeschir Ghofrani, Sanjay Mehta, Franck Olivier Le Brun

Publikováno v: European Heart Journal
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Aims The effect of macitentan on haemodynamic parameters and NT-proBNP levels was evaluated in pulmonary arterial hypertension (PAH) patients in the SERAPHIN study. Association between these parameters and disease progression, assessed by the primary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1707283470f2dd865b9f35e8486cf22c
http://europepmc.org/articles/PMC5400052

Zobrazit plný text záznamu

Effect of Macitentan on Hospitalizations

Autor: Nazzareno Galiè, Richard N. Channick, Pavel Jansa, B.K.S. Sastry, Hossein Ardeschir Ghofrani, Rogério Souza, Gérald Simonneau, Sanjay Mehta, Tomás Pulido, Olivier Sitbon, Marion Delcroix, Franck-Olivier Le Brun, Elke Hunsche, Lewis J. Rubin, Adam Torbicki

Publikováno v: JACC: Heart Failure. 3:1-8

Objectives This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary arterial hypertension (PAH). Background PAH is a progressive, life-threatening disease often requiring hospitalization. Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c7785063cb26ad369a07191f1e97955
https://doi.org/10.1016/j.jchf.2014.07.013

Zobrazit plný text záznamu

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

Autor: Raynaud Study Investigators, Eric Hachulla, Ariane L. Herrick, Jean Marie Frenoux, Christopher P. Denton, Gabriela Riemekasten, Aline Frey, Andreas Schwarting, Franck Olivier Le Brun

Publikováno v: Denton, C P, Hachulla, É, Riemekasten, G, Schwarting, A, Frenoux, J M, Frey, A, Le Brun, F O, Herrick, A L & Raynaud Study Investigators 2017, ' Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis : A Randomized, Placebo-Controlled, Phase II Study ', Arthritis and Rheumatology, vol. 69, no. 12, pp. 2370-2379 . https://doi.org/10.1002/art.40242

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545c60d1683a7037391a76ec7b0914e8
https://doi.org/10.1002/art.40242

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání